Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARIXTRA infusion · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| ARIXTRA infusion | DRUG | - |
| Enoxaparine infusion | DRUG | - |
Inclusion criteria: * Patients undergoing either an elective major hip or knee replacement or revision. * Signed written informed consent. Men or women of non-child bearing potential(i.e., post menopausal or with hysterectomy of bilateral tubule ligation) or women of childbearing potential without ...
ARIXTRA infusion is a small molecule drug in Phase 3 clinical development for the treatment of thromboembolism, a condition involving blood clots. It is being studied in patients undergoing knee or hip replacement surgery. The drug is administered as an infusion and is intended to address cardiovascular conditions related to abnormal blood clotting.
ARIXTRA infusion is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for the treatment of thromboembolism in patients undergoing joint replacement surgery.
ARIXTRA infusion is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial, which has been completed, was designed to evaluate the drug's efficacy and safety in patients with thromboembolism undergoing knee or hip replacement surgery.
ARIXTRA infusion has one completed Phase 3 clinical trial registered under the identifier NCT00328939. The trial, titled 'ARIXTRA Local Study For Registration In China,' enrolled 240 participants with thromboembolism, knee replacement, or hip replacement conditions. The study was conducted in China and included adults aged 18 years and older.
ARIXTRA infusion is a brand name for the drug fondaparinux, an anticoagulant used to prevent and treat blood clots. It is a synthetic small molecule that inhibits factor Xa, a key protein in the blood clotting cascade. The drug is administered as an infusion and is being studied for thromboembolism in patients undergoing knee or hip replacement surgery.